Weekly ReportJun 9–15, 2026
Sepsis, week 24 edition
We read 230 papers and selected 3.
Summary
This week’s sepsis literature highlights mechanistic and translational advances that converge on targetable host biology. A Cell Reports mechanistic study shows procalcitonin crosses the blood–brain barrier to perturb a VMPO–supraoptic vasopressin circuit, reframing PCT as an active mediator of fluid imbalance. Deep multi-omics in pediatric sepsis defines an IL-6/IFN-γ–driven endotype with baseline STAT1/3 hyperactivation, nominating JAK/STAT as a tractable target. Translational metabolic work links TCA-cycle–centric nutrition to improved neonatal infection defense, pointing to nutrition-based interventions.
Selected Articles
1. A hypothalamic VMPO-supraoptic vasopressin circuit mediates procalcitonin-induced fluid imbalance.
Preclinical mechanistic work shows systemic procalcitonin crosses the blood–brain barrier, activates calcitonin receptors on Oprk1+ VMPO neurons, and engages a VMPO–supraoptic vasopressin circuit that perturbs fluid and sodium homeostasis. The study reframes PCT from a passive biomarker to an active pathophysiologic mediator with a defined central targetable pathway.
Impact: Provides first-in-kind central neuroendocrine mechanism linking a widely used sepsis biomarker (PCT) to dysnatremia/volume derangements, opening new therapeutic entry points (e.g., calcitonin-receptor antagonists or vasopressin-pathway modulation).
Clinical Implications: Suggests reconsideration of PCT as only a biomarker; therapies targeting calcitonin-receptor signaling or downstream vasopressin circuits could mitigate sepsis-related dysnatremia and refractory volume disturbances after translational validation.
Key Findings
- Systemic procalcitonin crosses the blood–brain barrier and binds/activates calcitonin receptors in the hypothalamic VMPO.
- PCT depolarizes Oprk1-expressing VMPO neurons and recruits a VMPO–supraoptic vasopressin circuit.
- Activation of this circuit perturbs fluid and sodium balance, providing a mechanistic basis for PCT-associated dysnatremia in sepsis.
2. Aberrant STAT signaling and T cell dysregulation define a targetable pediatric sepsis endotype.
A prospective multi-omics cohort (n=88 critically ill children) integrated deep immune phenotyping, plasma proteomics, single-cell transcriptomics, and phosphoflow to identify an IL-6/IFN-γ–driven hyperinflammatory pediatric endotype. This endotype exhibited baseline STAT1/3 hyperactivation in CD8+ T cells with functional unresponsiveness to TCR stimulation, pointing to JAK/STAT pathway inhibition as a rational, biomarker-led therapeutic strategy.
Impact: Defines a mechanistically coherent, clinically relevant pediatric sepsis endotype with convergent multi-omic and functional evidence that nominates an actionable target (JAK/STAT) for biomarker‑guided trials.
Clinical Implications: Supports immune endotyping in pediatric sepsis to select patients for targeted immunomodulation (eg, JAK inhibitors or IL-6/IFN-γ modulators) in prospective, biomarker-enriched trials.
Key Findings
- Unsupervised clustering revealed an IL-6/IFN-γ–driven high-severity subgroup.
- CD8+ T cells in this group displayed baseline STAT1/STAT3 hyperactivation and failed to respond to TCR stimulation.
- Convergent multi-omic data nominate the JAK/STAT axis as a targetable pathway in this pediatric endotype.
3. Harnessing the glycolysis-TCA cycle axis to boost host defense against neonatal infection.
Translational work linking a 700‑child birth cohort and controlled neonatal piglet sepsis models shows higher plasma TCA metabolites correlate with fewer infections in infants, and that shifting nutritional substrates away from glycolysis toward TCA-driven oxidative metabolism (eg, substituting glucose with galactose or glucogenic amino acids) enhances pathogen clearance and survival in neonatal models.
Impact: Establishes a translational link between systemic energy metabolism and neonatal infection defense and proposes actionable, nutrition-based interventions that can be tested in early clinical trials.
Clinical Implications: Motivates re-evaluation of parenteral/enteral nutrition composition in high‑risk neonates and supports early-phase trials testing TCA-supportive formulations (eg, galactose or glucogenic amino acid enrichment) with infection and metabolic endpoints.
Key Findings
- In a 700-child birth cohort, higher plasma TCA-cycle metabolites associated with reduced infection burden and systemic inflammation.
- In neonatal piglet sepsis models, switching nutritional substrates to favor TCA-driven oxidative phosphorylation improved pathogen clearance and survival.
- Nutrition-induced hepatic rewiring from glycolysis to TCA flux mitigated inflammation and organ injury in preclinical models.